In this first article, note that in 2013, 3M licensed its Taper...

In this first article, note that in 2013, 3M licensed its Taper Model of DPI to Adamis Pharmaceuticals.
http://www.fiercedrugdelivery.com/story/3m-sells-dry-powder-inhaler-rights-adamis/2013-08-07

On the Adamis website they display a graph showing where they are at in the Product Pipeline Discovery stage - note
APC-5000 Dry Powder Inhaler designated to be used for Asthma/COPD is presently at Phase 2 results - ring a bell?

http://www.adamispharmaceuticals.com/products-specialty-pharmaceuticals.php



Then click on the APC-5000 model : http://www.adamispharmaceuticals.com/products-APC-5000.php
APC-5000 - Dry Powder Inhaler


APC-5000 is Adamis' first product using the Taper Dry Powder Inhalation (DPI) technology that the Company has fully acquired and exclusively licensed from 3M Drug Delivery Systems. The Taper DPI is a patented pre-metered device that Adamis expects will have a number of advantageous features when compared to competing DPI products including: greater efficiency, less dependence on the individual's inspiratory flow rate (due to the aerosolization energy inherent in the device), no need for excipients in most formulations, capability of delivering up to 120 doses (a two month supply), moisture protection, and ease of use. In addition, the device has been designed to reduce the likelihood of delivering a double dose.
Addressable Market ~$4.0 billion

According to IMS Health data, the global asthma and COPD prescription market is more than $34 billion and is averaging 7% growth per year. Also according to IMS, annual sales of the AdvairDiskus® (Glaxosmithkline model)
are currently in excess of $4 billion in the United States and $8 billion globally.

My comment:  I believe we're looking at a Pharmaceutical Company readying itself to take our product to market?
Hopefully it will be one of many Pharmas vying for this option & Adamis is just trying to look keen & ready to go?  

If you also read the article below comparing the 3M model with other brands it appears their DPI could be already ahead of the pack - here is an excerpt:

The 3MTM Taper DPI has demonstrated high efficiency with typical FPF of ~50%, a two-fold improvement over DISKUS®, Turbohaler®, and Easyhaler®. Predicted Taper lung dose is relatively insensitive to inhalation flow profile, similar to DISKUS®. Doses from 0.005 to 2 mg/actuation have been loaded and consistently delivered from Taper. Excellent stability was observed in the Taper device through 6 months storage (25ºC/60% RH).

http://solutions.3m.com/3MContentRe...assetId=1273684150144&blobAttribute=ImageFile

Anyway, I do feel in discovering these links that there is high anticipation that we are definately heading for Commercialisation. Happy reading!
Katy